It was demonstrated that irisin treatment activates the AMPK pathway and downregulates the mTOR pathway, thereby suppressing pancreatic cancer cell growth, and thus inhibits the epithelial–mesenchyme transition (EMT) of pancreatic cancer cells [31]. The gene discussed is MTOR; the disease is familial pancreatic carcinoma.